Publications
Telomelysin (OBP-301)
- ■The results from an investigator-initiated phase II clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab in advanced gastric and gastroesophageal junction (GEA) adenocarcinoma
Manish A. Shah（Weill Cornell Medicine）
ASCO（American Society of Clinical Oncology）, 2023- ■Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer
Takeshi Koujima, Hiroshi Tazawa, Takeshi Ieda, Hiroyuki Araki, Takuro Fushimi, Ryohei Shoji, Shinji Kuroda, Satoru Kikuchi, Ryuichi Yoshida, Yuzo Umeda, Fuminori Teraishi, Yasuo Urata, Hiroyuki Mizuguchi and Toshiyoshi Fujiwara
「Molecular Therapy Oncolytics」VOLUME 17, JUNE 26, 2020, P107-117, June 2020- ■Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
Terutaka Tanimoto, Hiroshi Tazawa, Takeshi Ieda, Hiroshi Nouso, Morimichi Tani, Takanori Oyama, Yasuo Urata, Shunsuke Kagawa, Takuo Noda, Toshiyoshi Fujiwara
「Molecular Therapy Oncolytics」Volume 18, 25 September 2020, Pages 14-231 June 2020.- ■Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam Histoculture and Tumor-Sphere Models of Chemo Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging
Shuya Yano, Kiyoto Takehara, Hiroshi Tazawa, Hiroyuki Kishimoto, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara, Robert M.Hoffman
PLOS ONE DOI:10.1371/Journal.pone.0162991 September27, 2016- ■Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer
Kiyoto Takehara, Hiroshi Tazawa,Naohiro Okada, Yuuri Hashimoto, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Yasuhiro Shiralawa, Nobuhiro Narii, Hiroyuki Mizuguchi, Yasuo Urata, Shunsuke Kagawa, and Toshiyoshi Fujiwara
Molecular Therpy, January2016 Ther;15(1), 2016- ■Biological Ablation of Sentinel Lymph Node Metastasis in Submucosally Invaded Early Gastrointestinal Cancer
Satoru Kikuchi, Hiroyuki Kishimoto, Hiroshi Tazawa, Yuuri Hashimoto, Shinji Kuroda, Masahiko Nishizaki, Takeshi Nagasaka, Yasuhiro Shirakawa, Shunsuke Kagawa, Yasuo Urata, Robert M Hoffman and Toshiyoshi Fujiwara
Molecular Therpy,mar2015 vol.23 no.3,501-509, 2015- ■Asimple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus
T Sasaki, H Tazawa, Hashimoto, S Yano, R Yoshida, S Kagawa, F Uno, Y Urata, T Ozagi, and T Fujiwara
Gene Therapy（2013）20,112-118, 2013- ■A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stek-like Cells in S/G2/M Phases
Shuya Yano, Hiroshi Tazawa, Yuuri Hashimoto, Yasuhiro Shirakawa, Shinji Kuroda, Masahiko Nishizaki, Hiroyuki Kishimoto, Futoshi Uno, Takeshi Nagasaka, Yasuo Urata, Shunsuke Kagawa, Robert M. Hoffman, and Toshiyoshi Fujiwara
Clinical Cancer Research, 19(23)December 1,2013, Dec. 2013- ■Enhanced antitumor efficacy of telomerase-selective oncolytic adenovirus with valproic acid against human cancer cell
Y Watanabe, Y Hahimoto, S Kagawa, H Kawamura, K Nagai, Y Urata and T Fujiwara
Cencer Gene Therapy(2012)19,,767-772, Oct. 2012- ■A novel apototic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression
Yasumoto Yamasaki, Haroshi Tazawa, Yuuri Hashimoto, Taru Kojimaa, Shinji Kuroda, Shuya Yano, Ryosuke Yoshida, Futoshi Uno, Hiroyuki Mizuguchi, Akira Ohtsuru, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara
European Journal of Cancer(2012)48,2282-2291, Aug. 2012- ■Clicical development directions in oncolytic viral therapy RM Eager1,2 and J Nemunaitis1,3,4
Mary Crowley Cancer Research Centers, Dallas, TX, USA; Department of Internal Medicine, TheUniversity of Hawaii, Honolulu, HI, USA; Texas Oncology PA Dallas, TX USA and Medical City Dallas Hospital, Dallas, TX, USA
Cancer Gene Therapy (2011)18,305-317, May 2011- ■Telomerase-Dependent Oncolytic Adenovirus Sensitizes Human Cancer Cells to lonzing Radiation via Inhibition of DNA Repair Machinery
Shinji Kuroda, Toshiya Fujiwara, Yasuhiro Shirakawa, Yasumoto Yamasaki, Shuya Yano, Futoshi Uno, Hiroshi Tazawa, Yuuri Hashimoto, Yuichi Watanabe, Kazuhiro Nomo, Yasuo Urata, Shunsuke Kagawa, and Toshiyoshi Fujiwara
CANCER RESEARCH, 70(22): Nov 15,2010, Nov. 2010- ■Preclinical Evaluation of Differentially Targeting Dual Virotherapy for Human Solid Cancer
Ryo Sakai, Shusuke Kagawa, Yasumoto Yamasaki, Toru Kojima, Futoshi Uno, Yuuri Hashimoto, Yuichi Watanabe, Yasuo Urata, Noriaki Tanaka1, and Toshiyoshi Fujiwara
Mol Cancer Ther, 9;8(4): June 2010, Aug. 2010- ■In Vivo Biological Purging forLymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy
Toru Kojima,MD, Yuichi Watanabe,PhD, Yuuri Hashimoto,BS, Shinji Kuroda,MD, Yasumoto Yamasaki,MD, Shuya Yano,MD, Masaaki Ouchi,BS, Hiroshi Tazawa,MD,PhD, Futoshi Uno,MD,PhD, Shunsuke Kagawa,MD,PhD, Satoru Kyo,MD,PhD,
Annals of Surgery Volume251, Number6, June 2010, Jun. 2010- ■A novel translational approach for human malignant pleural mesothelioma:heparnase-assisted dual virotherapy
Y Watanabe, T Kojima, S Kagawa, F Uno, Y Hashimoto, S Kyo, H Mizuguchi, N Tanaka, H Kawamura, D Ichimaru, Y Urata and T Fujiwara
Oncogene(2010)29.1145-1154, 2010- ■Antiumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma
NORIO KONDO, MAMORU TSUKUDA, MACHIKO KIMURA, KYOKO FUJITA, ATSUKO SAKAKIBARA, HIDEAKI TAKAHASHI, YUKARI ISHIGURO, GABOR TOTH and HIDEKI MATSUDA
.ONCOLOGY REPORTS.23：355-363.2010, Jan. 2010- ■A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus(Telomelysin) for Various Solid Tumors
John Nemunaitis, Alex W Tong, Michael Nemunaiitis, Neil Senzer, Anagha P Phadke, Cynthia Bedell, Ned Adams, Yu-An Zhang, Phillip B Maples, Salina Chen, Beena Pappen, James Burke, Daijyu Ichimaru, Yasuo Urata and Toshiyoshi Fujiwara
Molecular Therpy,Nov 2009, Nov. 2009- ■Preclinical evaluation of synergistic effect of telomerasespesific oncolytic viritherrapy and gemcitabine for human lung cancer
Dong Liu, Toru Kojima, Masaaki Ouchi, Shinji Kuroda, Yuichi Watanabe, Yuuti Hashimoto, Hideki Onimatsu, Yasuo Urata, and Toshiyoshi Fujiwara
Mol Cancer Ther, 2009;8(4): April 2009, Apr. 2009- ■Telomerase-Specific Virotheranostics for Human Head and Neck Cancer
Yuji Kurihara, Yuichi Watanabe, Hideki Onimatsu, Toru Kojima, Tatsuo Shitota, masashi Hatori, Dong Liu, Satoru Kyo, Hirosyuki Mizoguchi, Yasuo Urata, Satoru Shintani, and Toshiyoshi Fujiwara
Clinical Cancer Research, 2009;15(7): 2335-2343, Apr. 2009- ■Antiviral activity of cidofovir against telomerase-speciffic replication-selective oncolytic adenovirus, OBP-301(Telomelysin)
Masaaki Ouchi, Hitoshi Kawamura, Yasuo Urata, Toshiyoshi Fujiwara
Invest New Drugs, 2009 27: 241-245, 2009- ■A Novel Antiangiogenic Effect for Telomerase-Spaecific Virotherapy through Host Immune System
Yoshiko Ikeda, Toru Kojima, Shinji Kurada, Yohikatsu Endo, Ryo Sakai, Masayoshi Hioki, Hiroyuki Kishimoto, Futtoshi Uno, Shunsuke Kagawa, Yuichi Watanabe, Yuuri Hashimoto, Yasuo Urata, Noriaki Tanaka, and Toshiyoshi Fujiwara
The Journal of Immunology, 182: 1763-1769, 2009
- ■Telomerase-specific virotherapy in an animal model of human head and neck cancer
Oumi Nakajima, Atsuko Matsunaga, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara, and Koji Kawakami
Mol Cancer Ther, 2009;8(1): 171-177, Jan. 2009- ■Establishment of biological and pharmacokinetic assayas of telomerase-specific replication-selective adenovirus
Yuuri Hashimoto, Yuichi Watanebe, Yoshiko Shirakiya, Futoshi Uno, Shunsuke Kagawa, Hitoshi Kawamura, Katsuyuki Nagai, Noriaki Tanaka, Horomi Kumon, Yasuo Urata and Toshiyoshi Fujiwara
Cancer Sci, 99(2): 385-390, Feb. 2008- ■Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation
Y Eodo, R Sakai, M Ouchi, H Onimatsu, M Hioki, S Kagawa, F Uno, Y Watanabe, Y Urata, N Tanaka, and T Fujiwara
Onvogene(2008)27, 2375-2381, 2008- ■Telomerase-Specific Oncolytic Virotherapy for Human Cancer with the hTERT Promoter
Toshiya Fujiwara, Yasuo Urata, Noriaki Tanaka
Current Cancer Drug Targets, 7(2): 191-201, Jul. 2007- ■Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells
Takanori Watanabe, Masayoshi Hioki, Toshiya Fujiwara, Masahiko Nishizaki, Shunsuke Kagawa, Masaki Taki, Hiroyuki Kishimoto, Yoshikatsu Endo, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara
Experimental Cell Research, 312: 256–265, 2006- ■Visualization of Intrathoracically Disseminated Solid Tumors in Mice with Optical Imaging by Telomerase-Specific Amplification of a Transferred Green Fluorescent Protein Gene
-
Tatsuo Umeoka, Takeshi Kawashima, Shunsuke Kagawa, Fuminori Teraishi, Masaki Taki, Masahiko Nishizaki, Satoru Kyo, Katsuyuki Nagai, Yasuo Urata, Noriaki Tanaka, and Toshiyoshi Fujiwara
CANCER RESEARCH, 64(17): 6259-65, Sep. 1, 2004 - ■Telomerase-Specific Replication-Selective Virotherapyfor Human Cancer
-
Takeshi Kawashima, Shunsuke Kagawa, Naoya Kobayashi, Yoshiko Shirakiya, Tatsuo Umeoka, Fuminori Teraishi, Masaki Taki, Satoru Kyo, Noriaki Tanaka, and Toshiyoshi Fujiwara
Clinical Cancer Research, 10: 285-92, Jan. 1, 2004
OBP-702
- ■Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer
Takeshi Koujima, Hiroshi Tazawa, Takeshi Ieda, Hiroyuki Araki, Takuro Fushimi, Ryohei Shoji, Shinji Kuroda, Satoru Kikuchi, Ryuichi Yoshida, Yuzo Umeda, Fuminori Teraishi, Yasuo Urata, Hiroyuki Mizuguchi and Toshiyoshi Fujiwara
「Molecular Therapy Oncolytics」VOLUME 17, JUNE 26, 2020, P107-117, June 2020- ■Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
Terutaka Tanimoto, Hiroshi Tazawa, Takeshi Ieda, Hiroshi Nouso, Morimichi Tani, Takanori Oyama, Yasuo Urata, Shunsuke Kagawa, Takuo Noda, Toshiyoshi Fujiwara
「Molecular Therapy Oncolytics」Volume 18, 25 September 2020, Pages 14-231 June 2020.- ■Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells
Joe Hasei, Tsuyoshi Sasaki, Hiroshi Tazawa, Shuhei Osaki, Yasuaki Yamakawa, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Teppei Onishi, Futoshi Uno, Shunsuke Kagawa, Yasuo Urata, Toshifumi Ozaki, and Toshiyoshi Fujiwara
Mol Cancer Ther; 12(3); 314–25.- ■A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression
Yasumoto Yamasaki, Hiroshi Tazawa, Yuuri Hashimoto, Toru Kojima Shinji Kuroda, Shuya Yano, Ryosuke Yoshida, Futoshi Uno, Hiroyuki Mizuguchi, Akira Ohtsuru, Yasuo Urata, Shunsuke Kagawa,Toshiyoshi Fujiwara
European Journal of Cancer(2012)48,2282-2291, Aug. 2012
OBP-801
- ■Pluripotent epigenetic regulator OBP‑801 maintains filtering blebs in glaucoma filtration surgery model
Yuji Yamamoto, Atsushi Mukai, Toru Ikushima, Yasuo Urata, Shigeru Kinoshita, Junji Hamuro, Morio Ueno & Chie Sotozono
Scientific Reports (2020) 10:20936- ■FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
Outline：The combination treatment of HDAC inhibitor, OBP-801 with FGFR inhibitor, BGJ398 showed the synergistic inhibition of the growth in bladder cancer cells.
Published online on: December 1,2017
https://doi.org/10.3892/or.2017.6127 Pages: 627-632
https://www.ncbi.nlm.nih.gov/pubmed/29207153- ■The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Outline：The combination treatment of HDAC inhibitor, OBP-801 with eribulin showed the synergistic inhibition of the growth in TNBC cells.
Breast Cancer Research and Treatment, ISSN: 0167-6806 (Print) 1573-7217 (Online)
https://www.ncbi.nlm.nih.gov/pubmed/29752686- ■The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
Furutani A, Sowa Y, Fujiwara H, Otsuji E, Sakai T.
Oncol Res. 2014;21(5): 281-286. doi:, 2014- ■A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.
Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T.
013 Oct;43(4): 1080-1086. doi: 1, 2013- ■Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Yoshioka T, Yogosawa S, Yamada T, Kitawaki J, Sakai T.
2013 May;129(2): 425-32. doi:, 2013- ■YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, Masuoka Y, Orita M, Sasamata M, Matsushime H, Furuichi K, Sakai T.
2008 Mar;32(3): 545-55, 2008
OBP-601 (Censavudine)
- ■Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M
Lancet HIV. 2016 Jan;3(1):e13-22, 2016- ■The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
Smith RA, Raugi DN, Wu VH, Leong SS, Parker KM, Oakes MK, Sow PS, Ba S, Seydi M, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group.
Antimicrob Agents Chemother. 2015 Dec;59(12):7437-46., 2015- ■Dried blood spot analysis without dilution: Application to the LC-MS/MS determination of BMS-986001 in rat dried blood spot.
Yuan L, Schuster A, Shen JX, Garrison-Borowski P, Aubry AF.
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:201-9., 2015- ■Scalable Synthesis of the Potent HIV Inhibitor BMS-986001 by Non-Enzymatic Dynamic Kinetic Asymmetric Transformation (DYKAT).
Ortiz A, Benkovics T, Beutner GL, Shi Z, Bultman M, Nye J, Sfouggatakis C, Kronenthal DR
Angew Chem Int Ed Engl. 2015 Jun 8;54(24):7185-8., 2015- ■Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
Mausumee G, Frank S, Shawn C, Dara H, Zhao Y, Soleil PM, Sanderson TP, Michael G, Marc D.
Int J Toxicol. 2014 May 20;33(3):204-218, 2014- ■Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
Urata Y, Paintsil E, Cheng YC, Matsuda T, Sevinsky H, Hawthorne D, Bertz R, Hanna GJ, Grasela D, Hwang C.
J Clin Pharmacol. 2014 Jun;54(6):657-64., 2014- ■Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.
CAntivir Ther. 2014;19(2):179-89., 2014- ■The antiretroviral drug pipeline: prospects and implications for future treatment research.
Flexner C, Saag M.
Curr Opin HIV AIDS. 2013 Nov;8(6):572-8., 2013- ■BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue.
Wang F, Flint OP.
Antimicrob Agents Chemother. 2013 Dec;57(12):6205-12., 2013- ■In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Li Z, Terry B, Olds W, Protack T, Deminie C, Minassian B, Nowicka-Sans B, Sun Y, Dicker I, Hwang C, Lataillade M, Hanna GJ, Krystal M.
Antimicrob Agents Chemother. 2013 Nov;57(11):5500-8, 2013- ■Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Cotte L, Dellamonica P, Raffi F, Yazdanpanah Y, Molina JM, Boué F, Urata Y, Chan HP, Zhu L, Chang I, Bertz R, Hanna GJ, Grasela DM, Hwang C.
J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):346-54., 2013- ■Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet
Alexander AJ, Zhang L, Hooker TF, Tomasella FP.
J Pharm Biomed Anal. 2013 May 5;78-79:243-51., 2013- ■Improved ruggedness of an ion-pairing liquid chromatography/tandem mass spectrometry assay for the quantitative analysis of the triphosphate metabolite of a nucleoside reverse transcriptase inhibitor in peripheral blood mononuclear cells.
Zhao Y, Liu G, Liu Y, Yuan L, Hawthorne D, Shen JX, Guha M, Aubry A.
Rapid Commun Mass Spectrom. 2013 Feb 15;27(3):481-8, 2013- ■Intracellular Metabolism and Persistence of the Anti-Human Immunodeficiency Virus Activity of 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine, a Novel Thymidine Analog
Elijah Paintsil, Ginger E. Dutschman, Rong Hu, Susan P. Grill, Wing Lam, Masanori Baba, Hiromichi Tanaka, and Yung-Chi Cheng
Antimicrobial Agents And Chemotherapy, 51(11):3870-3879, Nov. 2007- ■Comparison of the Phosphorylation of 4'-Ethynyl 2',3'-Dihydro-3'-Deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs
Chih-Hung Hsu, Rong Hu, Ginger E. Dutschman, Guangwei Yang, Preethi Krishnan, Hiromichi Tanaka, Masanori Baba, and Yung-Chi Cheng
Antimicrobial Agents And Chemotherapy, 51(5):1687-1693, May 2007- ■Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine In Vitro
Takao Nitanda, Xin Wang, Hiroki Kumamoto, Kazuhiro Haraguchi, Hiromichi Tanaka, Yung-Chi Cheng, and Masanori Baba
Antimicrobial Agents and Chemotherapy, 49(8):3355-3360, Aug. 2005- ■Novel 4_-Substituted Stavudine Analog with Improved Anti-Human Immunodeficiency Virus Activity and Decreased Cytotoxicity
Ginger E. Dutschman, Susan P. Grill, Elizabeth A. Gullen, Kazuhiro Haraguchi, Shingo Takeda, Hiromichi Tanaka, Masanori Baba, and Yung-Chi Cheng
Antimicrobial Agents And Chemotherapy, 48(5):1640-1646, May 2004
TelomeScan (OBP-401 , OBP-1101)
- ■「Early Detection of Recurrence in Patients with Locally Advanced Non-small Cell Lung Cancer via Circulating Tumor Cell Analysis」
Chimbu Chinniah, BA, Louise Aguarin, MS, Phillip Cheng, BA, Cristina Decesaris,MD, Alicia Cutillo, MD, Abigail T. Berman, MD, Melissa Frick, BA, Abigail Doucette,MS, Keith A. Cengel, MD, PhD, William Levin, MD, Stephen Hahn, MD, Jay F.Dorsey, MD, PhD, Charles B. Simone, II, MD, Gary Kao, MD, PhD
『Clinical Lung Cancer』March 2019 Volume 20, Issue 2 May10, 2019- ■Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.
Outline：Outline：Detection and monitoring of circulating tumor cells (CTCs) may be useful in patients with early stage non-small lung cancer.
Melissa A. Frick, Gary D. Kao, Louise Aguarin,Chimbu Chinniah, Samuel Swisher-McClure,Abigail T. Berman,William P. Levin,Keith A. Cengel, Cristina DeCesaris, Stephen M. Hahn, Jay F. Dorsey, Charles B. Simone II
『International Journal of Radiation Oncology』 Volume 102, Issue 3, Pages 536–542 November 1, 2018- ■Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.
Outline：Relationship between therapeutic response and clinicopathological features using the tissue and liquid biopsy (CTC and cfDNA) from squamous cell lung cancer.
Junko Watanabe, Shinsaku Togo, Issei Sumiyoshi, Yukiko Namba, Kentaro Suina, Takafumi Mizuno, Kotaro Kadoya, Hiroaki Motomura, Moe Iwai, Tetsutaro Nagaoka, Shinichi Sasaki, Takuo Hayashi, Toshimasa Uekusa, Kanae Abe, Yasuo Urata, Fuminori Sakurai, Hiroyuki Mizuguchi, Shunsuke Kato and Kazuhisa Takahashi
Oncotarget, 2018; 9:24000-24013- ■Integrated fluorescent cytology with nano‐biologics in peritoneally disseminated gastric cancer
Megumi Watanabe, Shunsuke Kagawa, Kazuya Kuwada, Yuuri Hashimoto, Kunitoshi Shigeyasu, Michihiro Ishida, Shuichi Sakamoto, Atene Ito, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Shuta Tomida, Ryuichi Yoshida, Hiroshi Tazawa, Yasuo Urata, Toshiyoshi Fujiwara
Cancer Science, 04 August 2018- ■Efficient detection of Human circulating tumor cells withoout significant production of false-positive cells by a novel conditionally replicating adenovirus
Fuminori Sakurai, Nobuhiro Narii, Kyoko Tomita, Shinsaku Togo, Kazuhisa Takahashi, Mitsuhiro Machitani, Masahi Tachibana, Masaaki Ouchi, Nobuyoshi Katagiri, Yasuo Urata, Toshiyoshi Fujiwara, and Hiroyuki Mizuguchi
Molecular Methods&Clinical Development(2016)3, 16001;doi:10.1038/mtm.2016.1, 2016- ■Fluorescence-guided surgery of a Highl-metastastatic variant of human triple-negative breast cancer targeted with a cancerspecific GFP adenovirus prevents recurrence
Shuya Yano, Kiyoto Takehara, Shinji Miwa, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuo Urata, Shunsuke Kagawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M.Hoffman
Oncotarget, Advance Publications 2016, 2016- ■Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer
Kiyoto Takehara, Hiroshi Tazawa, Naohiro Okada, Yuuri Hashimoto, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Kishimoto, Yasuhiro Shiralawa, Nobuhiro Narii, Hiroyuki Mizuguchi, Yasuo Urata, Shunsuke Kagawa, and Toshiyoshi Fujiwara
Molecular Therpy, January2016 Ther;15(1), 2016- ■Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer patients undergoing definitive radiation therapy: Pilot study results.
Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, Simone CB 2nd, Hahn SM.
Cancer, 2014 Sep 19. [Epub ahead of print]- ■Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.
Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, Wileyto EP, Hahn SM, Dorsey JF.
Cancer Res. 2014 Feb 13. [Epub ahead of print]- ■テロメスキャンを用いた新しいCTC検出技術とその臨床応用
浦田 泰生, 片桐 伸悦
腫瘍内科 第11巻 第5号別刷 625-630 2013年5月発行科学評論社, May 2013- ■A novel approach using telomerasa-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients
Seung Jin Kim, Akinori Masaga, Yasuhiro Tamaki, Kenji Akazawa, Fumine Tsukamoto, Jin Sato, Toshiyuki Ozawa, Yukio Tsujino, Shinzaburo Noguchi
Breast Cancer Res Treat DOI 10.1007/s10549-011-1603-2, Feb. 2012- ■Preclinical Evalution of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas
Tsuyoshi Sasaki, Hiroshi Tazawa, Jo Hasei, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Syuya Yono, Ryosuke Yoshida, Futoshi Uno, Shunsuke Kagawa, Yuki Morimoto, Yasuo Urata, Toshifumi Ozaki, and Toshiyoshi Fujiwara
Clinical Cancer Research, 17(7)April 1,2011, Apr. 2011- ■In Vivo Biological Purging forLymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy
Toru Kojima,MD, Yuichi Watanabe,PhD, Yuuri Hashimoto,BS, Shinji Kuroda,MD, Yasumoto Yamasaki,MD, Shuya Yano,MD, Masaaki Ouchi,BS, Hiroshi Tazawa,MD,PhD, Futoshi Uno,MD,PhD, Shunsuke Kagawa,MD,PhD, Satoru Kyo,MD,PhD,
Annals of Surgery Volume251, Number6, June 2010, Jun. 2010- ■A simple biological imaging system for detecting viable human circulating tumor cell
Toru Kojima, Yuuri Hashimoto, Yuichi Watanabe, Shunsuke Kagawa, Futoshi Uno, Shinji Kuroda, Hiroshi Tazawa, Satiry Kyo, Hiroyuki Mizuguchi, Yasuo Urata, Noriyuki Tanaka, and Toshiyoshi Fujiwara
The Journal of Clinical Investigation, 119(10): 3172-3181, Oct. 2009- ■In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus
Hiroyuki Kishimoto, Toru Kojima, Yuichi Watanabe, Shunsuke Kagawa, Toshiya Fujiwara, Futoshi Uno, Fuminori Teraishi, Satoru Kyo, Hiroyuki Mizuguchi, Yuuri Hashimoto, Yasuo Urata, Noriaki Tanaka & Toshiyoshi Fujiwara
Nature Medicine, 12(10):1213-1219, Oct. 2006- ■Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy
Toshiya Fujiwara, Shunsuke Kagawa, Hiroyuki Kishimoto, Yoshikatsu Endo, Masayoshi Hioki, Yoshihiro Ikeda, Ryo Sakai,Yasuo Urata, Noriaki Tanaka and Toshiyoshi Fujiwara
International Journal of Cancer, 119:432-440, 2006- ■Visualization of intrathoracically Disseminated Solid Tumor in Mice with Optical Imaging by Telomerase-Specific Amplification of a Transferred Green Fluorescent Protein Gene.
Umeoka T., Kawashima T., Kagawa S., Teraishi F., Taki M., Nishizaki M., Kyo S., Nagai K., Urata Y., Tanaka N., Fujiwara T.
Cancer Research, 64(17):6259-6265, Sep. 2004
